dual agonist tirzepatide Tirzepatide, a GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction | Cardiovascular Diabetology 1 and GIP therapy Tirzepatide (LY3298176) is a Dual

Despite promising preclinical outcomes, their clinical translation is hindered by poor solubility, instability, and batch variability

ABCA1 is pivotal for HDL-C biogenesis and cholesterol efflux, whereas SR-B1 mediates uptake of HDL cholesteryl esters [37,38]

Research interest in Tirzepatide continues to grow due to scientific studies involving peptide signalling pathways and metabolic research models

It is classified as DPP -4 inhibitor or gliptin

Patients with diabetes for more than 5 years show a higher prevalence compared with those diagnosed more recently [6]

Continue taking these medications as per your doctors instructions, but you will be more susceptible to bruising after your injections